CARY, NC--(Marketwired - Nov 7, 2013) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX)
• Record quarterly net revenue of $53.7 million, up 43% compared to the third quarter of 2012
• Diluted earnings per share of $0.31, up $0.26 per share compared to third quarter of 2012
• Gross margin of 76%, a sharp rise from 62% in third quarter of 2012
• Initiated sales of PERTZYE® (pancrelipase) and our generic equivalent of Tussionex® (hydrocodone polistirex and chlorpheniramine polistirex)
Cornerstone Therapeutics Inc. (NASDAQ: CRTX), a specialty pharmaceutical company focused on commercializing products for the U.S. hospital and adjacent specialty markets, today announced results for the third quarter ended September 30, 2013.
Help employers find you! Check out all the jobs and post your resume.
